ISID Home
about ISID | membership | programs | publications | resources | 14th ICID | site map
 
ProMed Home
 
  Navegación
Portada (en inglés)
ProMED-ESP, español
Consultar los archivos en español
Suscripción y Cancelación ProMED-ESP
 
Archive Number 20091113.3934
Published Date 13-NOV-2009
Subject PRO/EDR> Mumps - USA (NY, NJ), Canada (QC)

MUMPS - USA (NEW YORK, NEW JERSEY), CANADA (QUEBEC)
***************************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Thu 12 Nov 2009
Source: CDC. MMWR Morb Mortal Wkly Rep 2009; 58 (dispatch): 1-4 [edited]
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58d1112a1.htm?s_cid=mm58d1112a1_e>


Mumps outbreak: New York, New Jersey, Quebec, 2009
--------------------------------------------------
Mumps is a vaccine-preventable viral infection characterized by fever  
and inflammation of the salivary glands and whose complications  
include orchitis, deafness, and meningo-encephalitis (1). In August  
2009, CDC was notified of the onset of an outbreak of mumps in a  
summer camp in Sullivan County, New York. The outbreak has spread and  
gradually increased in size and is now the largest US mumps outbreak  
since 2006, when the United States experienced a resurgence of mumps  
with 6584 reported cases (2). On [18 Aug 2009], public health  
departments in Sullivan County, New York state, and CDC began an  
investigation into the mumps outbreak, later joined by departments in  
New York City and other locales. As of [30 Oct 2009], a total of 179  
confirmed or probable cases had been identified from multiple  
locations in New York and New Jersey, and an additional 15 cases had  
been reported from Canada.

The outbreak has primarily affected members of a tradition-observant  
religious community; median age of the patients is 14 years, and 83  
percent are male. 3 persons have been hospitalized. Although little  
transmission has occurred outside the [religious] community, mumps can  
spread rapidly in congregate settings such as colleges and schools;  
therefore, public health officials and clinicians should heighten  
surveillance for mumps and ensure that children and adults are  
appropriately vaccinated.

Mumps cases in the United States have been classified according to the  
2008 case definition of the Council of State and Territorial  
Epidemiologists, and cases in Canada have been classified in  
accordance with Case Definitions for Diseases Under National  
Surveillance. Patients in the United States are considered to have  
age-appropriate vaccinations for mumps if they are aged 1-6 years and  
have received 1 dose of a mumps-containing vaccine, aged 7-18 years  
and have received 2 doses of vaccine, or aged 19-52 years and have  
received 1 dose of vaccine (3,4). Patients aged 7-18 years who have  
received 1 dose are considered to have received a partially  
age-appropriate vaccination.

Outbreak reports
----------------
Sullivan County, New York. On [18 Aug 2009], the New York State  
Department of Health was notified of mumps cases in a summer camp  
serving approximately 400 boys from the tradition-observant religious  
community. The index patient was a boy aged 11 years who had returned  
on [17 Jun 2009] from the United Kingdom, where a mumps outbreak is  
ongoing with approximately 4000 cases, primarily in unvaccinated young  
adults in the general population. The boy became symptomatic at camp  
on [28 Jun 2009]. A total of 25 cases were reported among camp  
attendees and staff members. The median age of patients was 12 years  
(range: 9-30 years), and all were male. Of the 24 patients for whom  
vaccination status was reported, 20 (83 percent) had received  
age-appropriate vaccination with 2 doses, one (4 percent) had received  
partial age-appropriate vaccination with 1 dose, and 3 (13 percent)  
were unvaccinated. The attack rate in this camp was approximately 6  
percent (25 of 400).

Brooklyn, New York. The majority of campers were residents of the  
Borough Park neighborhood of Brooklyn, where mumps transmission began  
after their return home from camp. Although returning campers were  
implicated in most of the initial exposures, no predominant focus of  
spread was identified. By [30 Oct 2009], 79 additional persons from  
Brooklyn or other boroughs who were linked to the outbreak had been  
reported, exclusive of returning campers. The median age of these  
patients was 14 years (range: 8 months-84 years), and 81 percent were  
male. Of the 61 patients (77 percent) for whom vaccine is recommended  
and vaccination status and age were reported, 47 (77 percent) had  
received age-appropriate vaccination, 6 (10 percent) had received  
partial age-appropriate vaccination, and 8 (13 percent) were  
unvaccinated.

Ocean County, New Jersey. On [26 Sp 2009], the New Jersey Department  
of Health and Senior Services was informed of 8 suspected mumps cases  
in 2 Ocean County private schools for boys with both boarder and  
commuter students from the same religious community. The index  
patient, who became symptomatic at one of the boarding schools on [6  
Sep 2009], was aged 20 years and a resident of the Borough Park  
neighborhood of Brooklyn, New York. Transmission was initially limited  
to the schools but subsequently was observed in households and the  
community. By [30 Oct 2009], a total of 40 cases had been reported.  
The median age of patients was 19.5 years (range: 1-65 years), and 83  
percent were male. Mumps vaccination status was reported for 29 (73  
percent) patients, of whom 28 (97 percent) had received  
age-appropriate vaccination.

Rockland County, New York. 4 of the patients who had attended the  
Sullivan County summer camp resided in Rockland County, New York. By  
[30 Oct 2009], an additional 27 cases (exclusive of returning campers)  
had been reported among members of the same religious community, with  
transmission occurring in a variety of settings, including a school  
for boys. The median age of patients was 12 years (range: 1-62 years),  
and 23 (85 percent) were male. Mumps vaccination status was reported  
for 19 (70 percent), of whom 11 had received age-appropriate  
vaccination, and 2 had received partial age-appropriate vaccination.

Orange County, New York. In September [2009], members of the same  
religious community in Orange County visited a synagogue in Brooklyn.  
During [8-14 Oct 2009], 8 cases occurred among the travelers. The  
median age of patients was 18 years (range: 11-23 years), and 5 were  
male. 7 patients had received age-appropriate vaccination with 2  
doses, and one was unvaccinated.

Quebec, Canada. Members of affected New York and New Jersey  
communities traveled to the province of Quebec to attend religious  
gatherings during [19 Sep-11 Oct 2009]. By [30 Oct 2009], 15 cases  
(patient age range: 8-47 years) from Montreal and the Laurentian  
region of the province had been reported to the Public Health Agency  
of Canada. All patients were male, and 11 had documented vaccination  
with at least 1 dose of mumps-containing vaccine.

Transmission outside the religious community
------------------------------------------------
During [28 Jun-30 Oct 2009], 5 cases outside the affected religious  
community were reported. 2 cases occurred in New York City, and 3  
occurred in Ocean County, New Jersey. The 2 New York City patients  
were a man aged 40 years who had probable worksite exposures to  
members of the affected community and a boy aged 4 years who had no  
identified exposure. The 3 New Jersey cases were patients aged 17, 29,  
and 66 years who had no identified exposures. 2 of the 5 patients had  
received 2 documented doses of mumps-containing vaccine, 1 had  
received 2 undocumented doses, and 2 had unknown vaccination status.

Laboratory testing
------------------
Of the 179 cases reported as of [30 Oct 2009] in the United States, 85  
(47 percent) have been laboratory-confirmed, and the remaining 94  
cases (53 percent) have met the clinical case definition. Laboratory  
tests used to confirm cases of mumps included detection of mumps  
immunoglobulin M antibodies by various methods, detection of mumps RNA  
by real-time reverse transcription-polymerase chain reaction (5), and  
isolation of mumps virus in cell culture. These tests were conducted  
by CDC and state and commercial laboratories. Mumps virus classified  
as genotype G was identified from multiple specimens sent to CDC,  
consistent with the probable importation of mumps into Sullivan County  
from the ongoing mumps outbreak in the United Kingdom (6).

Epidemiologic summary
---------------------
Of the 178 (99 percent) patients whose sex is known, 149 (84 percent)  
are male. The median age of the 178 patients for whom age is known is  
14 years (range: 8 months-84 years). Of the 141 patients (79 percent)  
for whom vaccine is recommended and vaccination status and age were  
reported, 113 (80 percent) had received age-appropriate vaccination, 9  
(6 percent) had received partial age-appropriate vaccination, and 19  
(13 percent) were unvaccinated. Of the 141 patients, 102 (72 percent)  
had received 2 doses, 20 (14 percent) 1 dose, and 19 (13 percent) zero  
doses.

Complications have occurred in 16 (9 percent) cases, including  
orchitis (15 cases) and temporary deafness (1 case). 3  
hospitalizations for orchitis have been reported. No deaths have  
occurred.

Response measures
-----------------
Health officials issued alerts in New Jersey, New York City, and  
elsewhere in New York state to health-care providers, urging them to  
increase active surveillance for mumps, to consider mumps diagnoses  
even if patients had documented vaccinations and, when indicated, to  
perform appropriate diagnostic testing. Isolation and quarantine  
procedures were reviewed, and health-care providers were urged to  
ensure that all children and adults were appropriately vaccinated.

[Reported by a long list of names, available at the source URL]

MMWR editorial note
-------------------
Before routine mumps vaccination was initiated, most persons acquired  
infection during childhood. In 1967, a live, attenuated mumps virus  
vaccine was licensed in the United States, and by 2005 high coverage  
with 2 doses among children had reduced the incidence of mumps by 99  
percent (2). In 2006, a resurgence occurred in the United States, with  
the highest attack rate among persons aged 18-24 years; 57 percent of  
patients had previously received 2 doses of vaccine (2). In 2007 and  
2008, incidence declined to 800 and 454 cases, and outbreaks involved  
fewer than 20 cases.

The ongoing mumps outbreak is the largest since 2006 and primarily has  
affected a tradition-observant religious community. Mumps outbreaks  
perpetuated by community transmission outside of congregate settings  
(such as, camps, schools, and colleges) are unusual in highly  
vaccinated populations (2). In this outbreak, the limited transmission  
of mumps into the general population might be attributable to  
generally high vaccination levels and little interaction between  
members of the affected religious community and persons in surrounding  
communities. Vaccination rates in the religious community in this  
outbreak have not been measured, but according to the 2008 National  
Immunization Survey, overall age-appropriate mumps vaccination rates  
for children in New York City, New York state, and New Jersey were  
high: 90 percent or higher for receipt of 1 dose among children aged  
19-35 months and 90 percent or higher for receipt of 2 doses among  
adolescents aged 13-17 years. However, mumps incidence commonly peaks  
in the winter (2), and vaccine-preventable diseases have spread from  
religious communities to the general population during the peak  
transmission season (7).

Of those patients in this outbreak whose vaccination status was known,  
72 percent had received 2 doses of mumps-containing vaccine, compared  
with 57 percent in the 2006 outbreak. Mumps vaccine effectiveness has  
been estimated at 73-91 percent for 1 dose and 76-95 percent for 2  
doses (8,9). Studies during the 2006 US mumps resurgence suggested  
that outbreaks could occur among highly-vaccinated populations such as  
college students, where frequent close contact occurs and where more  
than 10 years have passed since most of the population received a 2nd  
dose (9). However, even in such settings, attack rates were less than  
8 percent in 2006 for those with 2 doses, suggesting that the vaccine  
was highly effective in preventing disease for the vast majority of  
those exposed (9). In the current outbreak, the attack rate at the  
summer camp was approximately 6 percent.

Because 43 percent of the world's nations have no mumps vaccination  
program (10), and certain nations with mumps vaccination programs,  
such as the United Kingdom, have experienced large-scale outbreaks,  
the risk for mumps exposure is increased with foreign travel. When  
importations occur, congregate settings in the United States, such as  
colleges and schools, have been foci of indigenous mumps transmission  
(2).

When possible, persons with suspected mumps should be isolated for 5  
days after onset of parotitis and, if they visit a health-care  
setting, droplet precautions should be initiated immediately. Clinical  
specimens (both serum and buccal swabs) should be collected from  
persons with suspected mumps as soon as possible after symptom onset.  
Adults and children should receive age-appropriate vaccination.  
University students, health-care personnel, and persons with potential  
mumps outbreak exposure should have documentation of 2 doses of mumps  
vaccine or other proof of immunity to mumps. Although vaccination is  
not considered effective postexposure prophylaxis for mumps,  
non-immune contacts should be vaccinated with measles, mumps, rubella  
(MMR) vaccine to prevent risk from subsequent exposures. Any suspected  
mumps case should be reported to the health department in the area  
where the patient resides. Additional information regarding mumps  
vaccination is available at
<http://www.cdc.gov/vaccines/vpd-vac/mumps/default.htm#recs>.

References
----------
1. Plotkin SA, Rubin SA: Mumps vaccine. In: Plotkin SA, Orenstein WA,  
Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Elsevier; 2008:  
435-65.
2. Barskey AE, Glasser JW, LeBaron CW: Mumps resurgences in the United  
States: a historical perspective on unexpected elements. Vaccine 2009;  
27(44): 6186-95 [abstract available at
<http://www.ncbi.nlm.nih.gov/pubmed/19815120>].
3. CDC. Measles, mumps, and rubella -- vaccine use and strategies for  
elimination of measles, rubella, and congenital rubella syndrome and  
control of mumps: recommendations of the Advisory Committee on  
Immunization Practices (ACIP). MMWR 1998; 47(No. RR-8) [available at
].
4. CDC. Updated recommendations of the Advisory Committee on  
Immunization Practices (ACIP) for the control and elimination of  
mumps. MMWR 2006; 55: 629-30 [available at
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5522a4.htm>].
5. Boddicker JD, Rota PA, Kreman T, et al: Real-time reverse  
transcription-PCR assay for detection of mumps virus RNA in clinical  
specimens. J Clin Microbiol 2007; 45: 2902-8 [available at
<http://jcm.asm.org/cgi/content/full/45/9/2902>].
6. Rota JS, Turner JC, Yost-Daljev MK, et al: Investigation of a mumps  
outbreak among university students with two measles-mumps-rubella  
(MMR) vaccinations, Virginia, September-December 2006. J Med Virol  
2009; 81(10): 1819-25 [abstract available at
<http://www.ncbi.nlm.nih.gov/pubmed/19697404>].
7. Parent du Chatelet I, Floret D, Antona D, et al: Measles resurgence  
in France in 2008, a preliminary report. Eurosurveill 2009; 14(6): 5-7  
[available at
<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19118>].
8. Dayan GH, Rubin S: Mumps outbreaks in vaccinated populations: are  
available mumps vaccines effective enough to prevent outbreaks? Clin  
Infect Dis 2008; 47(11): 1458-67 [available at
<http://www.journals.uchicago.edu/doi/full/10.1086/591196>].
9. Marin M, Quinlisk P, Shimabukuro T, et al: Mumps vaccination  
coverage and vaccine effectiveness in a large outbreak among college  
students - Iowa, 2006. Vaccine 2008; 26(29-30): 3601-7 [abstract  
available at
,http://www.ncbi.nlm.nih.gov/pubmed/18539365>].
10. World Health Organization. Global status of mumps immunization and  
surveillance. Wkly Epidemiol Rec 2005; 80:418-24 [available at
<http://www.who.int/wer/2005/wer8048.pdf>].

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[This ongoing mumps outbreak is the largest since 2006 and primarily  
has affected a religious community. Mumps vaccine effectiveness has  
been estimated at 73-91 percent for 1 dose and 76-95 percent for 2  
doses. Thus, outbreaks may occur among highly vaccinated populations  
such as college students, where frequent close contact occurs and  
where more than 10 years have passed since most of the population  
received a 2nd dose.

The MMWR recommendation is that public health officials should be  
aware that a mumps outbreak is ongoing, consider the diagnosis of  
mumps in patients with symptoms consistent with the disease, and  
ensure that children and adults (particularly in congregate settings  
such as universities and hospitals) have received an appropriate  
number of MMR vaccine doses. - Mod.CP]

[see also:
Mumps - USA (04): (NY) 20091106.3835
Mumps - USA (03): (NY) 20091023.3655
Mumps - USA (02): (MA), students 20090917.3265
Mumps: USA (MA); UK (Scotland) 20090419.1482
Mumps - USA: (MA) ex Ireland 20090417.1455]
........................................cp/mj/jw
*##########################################################*
************************************************************
ProMED-mail makes every effort to  verify  the reports  that
are  posted,  but  the  accuracy  and  completeness  of  the
information,   and  of  any  statements  or  opinions  based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by  ProMED-mail.   ISID
and  its  associated  service  providers  shall not be  held
responsible for errors or omissions or  held liable for  any
damages incurred as a result of use or reliance upon  posted
or archived material.
************************************************************
Become     a    ProMED-mail    Premium     Subscriber     at
<http://www.isid.org/ProMEDMail_Premium.shtml>
************************************************************
Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send  all  items  for   posting  to:   promed@promedmail.org

(NOT to  an  individual moderator).  If you do not give your
full name and  affiliation, it  may  not  be  posted.   Send
commands  to  subscribe/unsubscribe,   get  archives,  help,
etc. to: majordomo@promedmail.org.    For assistance  from a
human  being  send  mail  to:   owner-promed@promedmail.org.

############################################################
############################################################

about ISID | membership | programs | publications | resources
14th ICID | site map | ISID home

©2001,2009 International Society for Infectious Diseases
All Rights Reserved.
Read our privacy guidelines.
Use of this web site and related services is governed by the Terms of Service.